Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q1 FY23 Earnings Presentation
25 slides from Shilpa Medicare's earnings presentation, Aug 12, 2022
Slide 1: Shilpa Medicare Limited
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 12 August 2022 Corporate Relationship Department
Slide 2: Q1 FY23 Results Presentation
Shilpa Medicare Limited (SML) Q1 FY23 Results Presentation 1
Slide 3: Disclaimer
2 Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and API Units, Raichur many other factors that could cause our actual
Slide 4: Table of content
Table of content 3 1 Company overview 2 Financial performance 3 Business highlights 4 Annexures
Slide 5: Company Overview
Company Overview 4
Slide 6: Company Overview
Company Overview 5 Pursuing niche growth businesses like Biologics, Transdermal & Oral Dissolving Films Formulations Established presence in Active Pharmaceutical Ingredients (APIs) and Formulations for Affordable & Robust research domestic & international markets Effective orientation resulting in
Slide 7: Managing Director's Message
Managing Director’s Message 6 Commenting on Q1 FY’23 performance, Mr. Vishnukant Bhutada, Managing Director Shilpa Medicare Limited said “Q1 FY’23 has been a challenging quarter for the company where we saw a down trend in both API and Formulation. The prevailing inflationary trends in the overall m
Slide 8: Financial Performance
Financial Performance 7
Slide 9: Reported Standalone Statement of Profit and Loss
Reported Standalone Statement of Profit and Loss 8 (INR in Cr.) Particulars Q1 FY23 Q4 FY22 % change Q1 FY21 % change Revenues 73.5 83.2 (11.7) 114.9 (36.1) Gross Margin 63.9 72.6 (12.0) 82.6 (22.6) Gross Margin % 87% 87% 1.0 72% 21.1 Employee Cost 27.9 30.1 (7.0) 24.3 15.0 Other Expenses 18.9 33.8
Slide 10: Reported Consolidated Profit and loss account
Reported Consolidated Profit and loss account 9 (INR in Cr.) Particulars Q1 FY23 Q4 FY22 % change Q1 FY21 % change Revenues 269.3 346.1 (22.2) 239.3 12.5 Gross Margin 165.3 232.5 (28.9) 163.4 1.2 Gross Margin % 61% 67% 68% (10.1) Employee Cost 72.9 73.4 (0.8) 57.9 25.9 Other Expenses 63.8 79.9 (20.2
Slide 11: Business Highlights
Business Highlights 10
Slide 12: Business overview
Business overview 11 Regulatory Achievements: US FDA Initiation of US Audit for Analytical Service Division in Unit VII based in Nacharam Hyderabad Concluded Remote Record Review by US FDA of Unit III Advanced Analytical Characterisation Laboratory situated at Slump sale transaction was complete
Slide 13: Q1 FY'23 Consolidated Performance
Q1 FY’23 Consolidated Performance 12 (INR in Cr.) Revenue EBIDTA 12% -22% -15% -64% 346.1 269.3 239.3 79.2 28.7 33.9 % to Sales 20% 11% 14% Q4 FY'22 Q1 FY'23 Q1 FY'22 Q4 FY'22 Q1 FY'23 Q1 FY'22 PBT PAT 46.5 -27% -91% 26.7 5.2 -4.1 2.3 3.1 Q4 FY'22 Q1 FY'23 Q1 FY'22 Q4 FY'22 Q3 FY'23 Q1 FY'22
Slide 14: Consolidated Revenue Break-up – Q1 FY'23
Consolidated Revenue Break-up – Q1 FY’23 13 (INR in Cr.) Q4 FY’22 Q1 FY’23 Q1 FY’22 INR 346.1cr. INR 269.3cr. INR 239.3cr. Growth of 13% vs Q1 FY’22 API 29.3, 9% 16, 6% 8.7, 4% Formulation Others 87.2 , 25% 68.8 , 26% 95.3 , 40% 229.6 , 66% 135.4 , 56% 184.5 , 68% Degrowth of 22% vs Q4 FY’22
Slide 15: API Business
API Business | noting affordable healthcare
Slide 16: API Business-Highlights Q1 FY'23
API Business-Highlights Q1 FY’23 15 (INR in Cr.) Oncology CRAMS -77% -26% 6% 134.2 23.1 98.7 93.0 5.3 % % contribution 58% Growth contribution 10% 3% No 54% 69% of API Sales 36% of API Sales Income FY'22 Q4 FY'23 Q1 FY'22 Q1 FY'22 Q4 FY'23 Q1 FY'22 Q1 FY’22 Q4 FY’23 Q1 FY’22 Q1 Non Oncology Others 2
Slide 17: DMF Filing update
DMF Filing update 16 New product introduction and increase in geographical coverage replicated with 212 number of DMF filings done with major regulatory authorities 45 45 31 20 18 16 12 9 7 7 2 US FDA EU/ EMEA GCC / ROW MFDS TPD-Canada TGA CHINA PMD RUSSIA MEDSAFE WHO As on 30th June 2022
Slide 18: Formulation Business
17 Formulation Business
Slide 19: Formulation Business-Highlights Q1 FY'23
Formulation Business-Highlights Q1 FY’23 18 (INR in Cr.) Europe License Fees ROW -91% -25% -19% -15% 593% -65% 49.9 21.2 2.1 43.8 17.1 37.4 % 2.5 % contribution % 0.2 0.5 contribution 57% 24% 25% contribution 54% 46% of For. Sales 3% of For. Sales of For. Sales 2% 0% 1% FY'22 Q4 FY'23 Q1 FY'22 Q1 FY
Slide 20: Regulatory Filings
Regulatory Filings 19 Robust regulatory filings to strength the base for growth in the formulation segment Approved Pending 334 26 26 6 211 13 18 5 20 13 3 13 123 2 1 US ANDA (SML) US NDA (SML) US ANDA (Customer) EU Filings ROW As on 30th June 2022
Slide 21: Annexures
Annexures 20
Slide 22: Manufacturing Excellence
Manufacturing Excellence 21 Dharwad Jadcherla Unit • Biologicals Manufacturing plant & R&D • Formulations (Onco & Adjuvant Therapy Facility • of Onco – Injectable & Oral) Bengaluru Unit Hyderabad • Formulations (Oral Dissolving Films) • TDS & ODF Manufacturing Facility & • Bio Analytical Lab, Pharma
Slide 23: Giving back to society
Giving back to society 22 Shilpa Medicare Limited works with Shilpa Foundation to carry out various CSR activities below are few of the many activities carried out in Q1 FY’23 Donated Tractor and 5,000 Liters water tank to green Raichur organization for watering the plants 1. Conducted Health camp f
Slide 24: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. 23 Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated marke
Slide 25: Thank You
24 Thank You